{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Import Library\n",
    "\n",
    "import openai\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.identity import AzureDeveloperCliCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.indexes import SearchIndexClient\n",
    "from azure.search.documents.indexes.models import (\n",
    "    HnswParameters,\n",
    "    PrioritizedFields,\n",
    "    SearchableField,\n",
    "    SearchField,\n",
    "    SearchFieldDataType,\n",
    "    SearchIndex,\n",
    "    SemanticConfiguration,\n",
    "    SemanticField,\n",
    "    SemanticSettings,\n",
    "    SimpleField,\n",
    "    VectorSearch,\n",
    "    VectorSearchAlgorithmConfiguration,\n",
    ")\n",
    "from azure.storage.blob import BlobServiceClient\n",
    "\n",
    "import openai\n",
    "import os\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores.azuresearch import AzureSearch\n",
    "\n",
    "import openai\n",
    "import os\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores.azuresearch import AzureSearch\n",
    "\n",
    "from azure.storage.blob import BlobServiceClient\n",
    "from azure.core.exceptions import ResourceExistsError\n",
    "import json\n",
    "\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "#from langchain.retrievers import AzureCognitiveSearchRetriever\n",
    "from langdetect import detect\n",
    "from langchain.prompts import PromptTemplate\n",
    "import re\n",
    "# Create chain to answer questions\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chains import LLMChain\n",
    "\n",
    "# Import Azure OpenAI\n",
    "from langchain.llms import AzureOpenAI \n",
    "from langchain.chat_models import AzureChatOpenAI\n",
    "from langchain.schema import HumanMessage\n",
    "\n",
    "#import textwrap\n",
    "import logging\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "\"\"\"#setting up credentials\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"] = \"gptdemosearch\" # replace with yours search service name\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"] = \"PcAZcXbX2hJsxMYExc2SnkMFO0D94p7Zw3Qzeu5WjYAzSeDMuR5O\" # replace with your api key\n",
    "os.environ[\"AZURE_INDEX_NAME\"] = \"sino-hr-chatbot\" #\"namfung-finance-chatbot\" # \n",
    "# end setting up credentials\"\"\"\n",
    "\n",
    "# setting up credentials\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"] = \"acs-testing-sunny\" # replace with yours search service name\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"] = \"oygYftyrBXiWoDLoZatDKNSLFttn9frM6DE4XlSb7kAzSeBR01eY\" # replace with your api key\n",
    "os.environ[\"AZURE_INDEX_NAME\"] = \"your-index-name\" #\"namfung-finance-chatbot\" # \n",
    "# end setting up credentials\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_prompt():\n",
    "    prompt_template_string=\"\"\"\n",
    "    Follow exactly these 5 steps:\n",
    "    1. Read the context below and aggregrate this data\n",
    "    Context : {context}\n",
    "    2. Answer the question using only this context\n",
    "    3. Answer the question in less than 200 words\n",
    "    4. Please provide the page number of the page where your answer is based on \n",
    "    5. Please provide the page number in the following output format: [Page: 1]\n",
    "    \n",
    "    User Question: {question}\n",
    "\n",
    "\n",
    "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "    return prompt_template\n",
    "\n",
    "def generate_prompt_chi():\n",
    "    prompt_template_string=\"\"\"\n",
    "    指令：\n",
    "    1. 你必须只根据以下文本的内容回答提问者的询问。\n",
    "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
    "    3. 请以少於200字回答问题。\n",
    "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
    "    \n",
    "    文本：{context}\n",
    "    #####\n",
    "\n",
    "    问题：{question}\n",
    "\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "    return prompt_template\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def initialize_vector_store():\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "    \n",
    "    # set up openai environment\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    search_service = os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"]\n",
    "    search_api_key = os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"]\n",
    "    vector_store_address: str = f\"https://{search_service}.search.windows.net\"\n",
    "    vector_store_password: str = search_api_key\n",
    "    \n",
    "\n",
    "    # define embedding model for calculating the embeddings\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    embeddings: OpenAIEmbeddings = OpenAIEmbeddings(deployment=model, chunk_size=1)\n",
    "    embedding_function = embeddings.embed_query\n",
    "\n",
    "    # define schema of the json file stored on the index\n",
    "    fields = [\n",
    "            SimpleField(\n",
    "                name=\"id\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                key=True,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"content\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            SearchField(\n",
    "                name=\"content_vector\",\n",
    "                type=SearchFieldDataType.Collection(SearchFieldDataType.Single),\n",
    "                searchable=True,\n",
    "                vector_search_dimensions=len(embedding_function(\"Text\")),\n",
    "                vector_search_configuration=\"default\",\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"metadata\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field to store the title\n",
    "            SearchableField(\n",
    "                name=\"title\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"source\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"page\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"website_url\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "        ]    \n",
    "    \n",
    "    vector_store: AzureSearch = AzureSearch(\n",
    "        azure_search_endpoint=vector_store_address,\n",
    "        azure_search_key=vector_store_password,\n",
    "        index_name=index_name,\n",
    "        embedding_function=embedding_function,\n",
    "        fields=fields,\n",
    "    )\n",
    "    \n",
    "    return vector_store"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def azure_search_by_index(question, index_name):\n",
    "\n",
    "    # set up openai environment\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    search_service = os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"]\n",
    "    search_api_key = os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"]\n",
    "    vector_store_address: str = f\"https://{search_service}.search.windows.net\"\n",
    "    vector_store_password: str = search_api_key\n",
    "    \n",
    "\n",
    "    # define embedding model for calculating the embeddings\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    embeddings: OpenAIEmbeddings = OpenAIEmbeddings(deployment=model, chunk_size=1)\n",
    "    embedding_function = embeddings.embed_query\n",
    "\n",
    "    # define schema of the json file stored on the index\n",
    "    fields = [\n",
    "            SimpleField(\n",
    "                name=\"id\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                key=True,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"content\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            SearchField(\n",
    "                name=\"content_vector\",\n",
    "                type=SearchFieldDataType.Collection(SearchFieldDataType.Single),\n",
    "                searchable=True,\n",
    "                vector_search_dimensions=len(embedding_function(\"Text\")),\n",
    "                vector_search_configuration=\"default\",\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"metadata\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field to store the title\n",
    "            SearchableField(\n",
    "                name=\"title\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"source\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"page\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"website_url\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "        ]    \n",
    "    \n",
    "    vector_store: AzureSearch = AzureSearch(\n",
    "        azure_search_endpoint=vector_store_address,\n",
    "        azure_search_key=vector_store_password,\n",
    "        index_name=index_name,\n",
    "        embedding_function=embedding_function,\n",
    "        fields=fields,\n",
    "    )\n",
    "\n",
    "    relevant_documentation = vector_store.similarity_search(query=question, k=1, search_type=\"similarity\")\n",
    "    \n",
    "    context = \"\\n\".join([doc.page_content for doc in relevant_documentation])[:10000]\n",
    "\n",
    "    lang = detect(context)\n",
    "\n",
    "    #print(doc)\n",
    "    #print(context)\n",
    "    #print(relevant_documentation)\n",
    "    source = relevant_documentation[0].metadata['source']\n",
    "    #page_no = relevant_documentation[0].metadata['page']\n",
    "    website_url = relevant_documentation[0].metadata['website_url']\n",
    "    \n",
    "    page_no = \"\"\n",
    "    for doc in relevant_documentation:\n",
    "        page_no = page_no + \",\" + doc.metadata['page'] \n",
    "    \n",
    "    #print(relevant_documentation[0])\n",
    "    #print(source)\n",
    "    #print(page_no)\n",
    "    #print(website_url)\n",
    "    #return str(context), source, website_url, lang, page_no\n",
    "    # just return 10 documents (i.e. pages) if number of pages return from the search result > 10\n",
    "    if len(relevant_documentation) > 10:\n",
    "        relevant_documentation = relevant_documentation[0:9]\n",
    "    else:\n",
    "        relevant_documentation = relevant_documentation\n",
    "    return relevant_documentation, source, website_url, lang, page_no\n",
    "\n",
    "\n",
    "# helper function to extract page number\n",
    "def extract_page_no(string):\n",
    "    if \"[Page\" in string:\n",
    "        print(re.findall('\\[Page:.*\\]', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\[Page:.*\\]', string)[0].split(':')[1].split(\"]\")[0].strip()\n",
    "    else:\n",
    "        return \"/\"\n",
    "\n",
    "def extract_answer(string):\n",
    "    if \"[Page\" in string:\n",
    "        return string.split(\"[Page\")[0]\n",
    "    else:\n",
    "        return string\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import LLMChain\n",
    "from langchain.llms import AzureOpenAI \n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chat_models import AzureChatOpenAI\n",
    "from langchain.memory import CosmosDBChatMessageHistory\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_prompt_with_history():\n",
    "    prompt_template_string=\"\"\"\n",
    "    Follow exactly these 6 steps:\n",
    "    1. Read the context below and aggregrate this data\n",
    "    Context : {context}\n",
    "    2. Answer the question using only this context and the chat history below\n",
    "    3. Answer the question in less than 200 words\n",
    "    4. Please provide the page number of the pages where your answer are based on at the end of your response\n",
    "    5. Please provide the page numbers in the following output format: [Page: 1, 2, 3]\n",
    "    6. Allow the chat continue by following Chat History\n",
    "    \n",
    "    Chat History: {chat_history}\n",
    "\n",
    "    User Question: {question}\n",
    "\n",
    "\n",
    "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\", \"chat_history\"])\n",
    "\n",
    "    return prompt_template\n",
    "\n",
    "def generate_prompt_chi_with_history():\n",
    "    prompt_template_string=\"\"\"\n",
    "    指令：\n",
    "    1. 你必须只根据以下文本的内容及谈话记录回答提问者的询问。\n",
    "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
    "    3. 请以少於200字回答问题。\n",
    "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
    "    5. 通过谈话记录允许聊天继续\n",
    "    \n",
    "    文本：{context}\n",
    "\n",
    "    谈话记录：{chat_history}\n",
    "\n",
    "    #####\n",
    "\n",
    "    问题：{question}\n",
    "\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\", \"chat_history\"])\n",
    "\n",
    "    return prompt_template\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import ConversationalRetrievalChain\n",
    "\n",
    "# helper function to extract page number\n",
    "def extract_page_no(string):\n",
    "    if \"[Page\" in string:\n",
    "        print(re.findall('\\[Page:.*\\]', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\[Page:.*\\]', string)[0].split(':')[1].split(\"]\")[0].strip()\n",
    "    elif \"(Page:\" in string: # handling for exception\n",
    "        print(re.findall('\\(Page:.*\\)', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\(Page:.*\\)', string)[0].split(':')[1].split(\")\")[0].strip()\n",
    "    else:\n",
    "        return \"/\"\n",
    "\n",
    "def extract_answer(string):\n",
    "    if \"[Page\" in string:\n",
    "        return string.split(\"[Page\")[0]\n",
    "    else:\n",
    "        return string\n",
    "\n",
    "def llm_pipeline_with_history(question):\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "\n",
    "    # retrieve information from Azure Search\n",
    "    relevant_docs, source, website_url, language, page_no = azure_search_by_index(question, index_name)\n",
    "\n",
    "    language = detect(question)\n",
    "\n",
    "    if language == \"en\":\n",
    "    #english prompt\n",
    "        QA_CHAIN_PROMPT = generate_prompt_with_history()\n",
    "    else:\n",
    "        QA_CHAIN_PROMPT = generate_prompt_chi_with_history()\n",
    "\n",
    "    # use AzureChatOpenAI \n",
    "    llm = AzureChatOpenAI(deployment_name=\"gpt-35-16k\", temperature=0,\n",
    "                        openai_api_version=\"2023-05-15\", openai_api_base=\"https://pwcjay.openai.azure.com/\")\n",
    "\n",
    "\n",
    "    \"\"\"    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://gpt-demo-chat-history.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"AZEhMpW4YD3t7iEMgp9at48S7f5ZjvnahUqJMYjMjMpH2QH2wiYBL97RdX7AqL3CMQcGGhbdAFHvACDbDDwMyA==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"sino_demo\"\n",
    "    CONTAINER_NAME = \"sino_chat_history\"\"\"\n",
    "    \n",
    "    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://acs-testing-sunny.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"UyxAxYPy6nhqLoTVhbs7C8NknhHoaRJuFkBaZramSAEPzNsHU0dhanOTRr2AJOjtqA1m0d5N3ujkACDbNmxrAQ==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"acs-fda-sunny\"\n",
    "    CONTAINER_NAME = \"acs-fda-cosmo\"\n",
    "\n",
    "    # session id, to be provided by frontend\n",
    "    sessionId = \"108\"\n",
    "    user_id = \"guest\"\n",
    "\n",
    "    history = CosmosDBChatMessageHistory(\n",
    "        cosmos_endpoint = ENDPOINT,\n",
    "        cosmos_database = DATABASE_NAME,\n",
    "        cosmos_container = CONTAINER_NAME,\n",
    "        credential = KEY,\n",
    "        session_id = sessionId,\n",
    "        user_id = user_id,\n",
    "    )\n",
    "\n",
    "    history.prepare_cosmos()\n",
    "\n",
    "    vector_store =initialize_vector_store()\n",
    "    \n",
    "    relevant_documentation = vector_store.similarity_search(query=question, k=1, search_type=\"similarity\")\n",
    "    \n",
    "    context = \"\\n\".join([doc.page_content for doc in relevant_documentation])[:10000]\n",
    "\n",
    "    #lang = detect(question)\n",
    "\n",
    "    #print(doc)\n",
    "    #print(context)\n",
    "    #print(relevant_documentation)\n",
    "    source = relevant_documentation[0].metadata['source']\n",
    "    #page_no = relevant_documentation[0].metadata['page']\n",
    "    website_url = relevant_documentation[0].metadata['website_url']\n",
    "\n",
    "    retriever = vector_store.as_retriever()\n",
    "\n",
    "    # add chat memory\n",
    "    memory = ConversationBufferMemory(\n",
    "        llm = llm,\n",
    "        output_key='answer',\n",
    "        memory_key='chat_history',\n",
    "        chat_memory=history,\n",
    "        return_messages=True\n",
    "    )\n",
    "\n",
    "    #QA_CHAIN_PROMPT = generate_prompt_with_history()\n",
    "\n",
    "    # The chain\n",
    "    chain = ConversationalRetrievalChain.from_llm(\n",
    "        llm,\n",
    "        retriever=retriever,\n",
    "        memory=memory,\n",
    "        combine_docs_chain_kwargs={\"prompt\": QA_CHAIN_PROMPT},\n",
    "        verbose=True,\n",
    "    )\n",
    "\n",
    "    #QA_CHAIN_PROMPT = PromptTemplate.from_template(template)\n",
    "\n",
    "    output = chain({\"question\": question})\n",
    "    \n",
    "    logging.info(output)\n",
    "    answer_value = output[\"answer\"]\n",
    "    # \n",
    "    language = \"-\"\n",
    "    \n",
    "    page_no = \"\"\n",
    "    for doc in relevant_documentation:\n",
    "        page_no = page_no + \",\" + doc.metadata['page'] \n",
    "        \n",
    "    logging.info(page_no)\n",
    "\n",
    "    if page_no == \"/\" or page_no == \"N/A\":\n",
    "        source = \"-\"\n",
    "        website_url = \"/\"\n",
    "\n",
    "    # extract first page number\n",
    "    if \",\" in page_no:\n",
    "        first_page_no  = page_no.split(\",\")[0]\n",
    "    else:\n",
    "        first_page_no = page_no\n",
    "    \n",
    "    page_no = extract_page_no(answer_value)\n",
    "    answer = extract_answer(answer_value)\n",
    "    \n",
    "    #return answer_value\n",
    "    \n",
    "    json_response = {\n",
    "        \"raw\": output,\n",
    "        \"answer\": answer,\n",
    "        \"source\": source,\n",
    "        \"website_url\": website_url,\n",
    "        \"page_no\": page_no,\n",
    "        \"first_page_no\": first_page_no,\n",
    "        \"language\": language\n",
    "    }\n",
    "    return json_response\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mGiven the following conversation and a follow up question, rephrase the follow up question to be a standalone question, in its original language.\n",
      "\n",
      "Chat History:\n",
      "\n",
      "Human: Can you explain the difference between bioavailability and bioequivalence?\n",
      "Assistant: Bioavailability refers to the rate and extent to which an active drug ingredient is absorbed from a drug product and becomes available at the site of action. It is a measure of the amount of drug that reaches the systemic circulation and the rate at which it reaches it. Bioavailability studies are conducted to determine the pharmacokinetic profile of a drug, including its absorption, distribution, metabolism, and excretion.\n",
      "\n",
      "On the other hand, bioequivalence refers to the similarity in the rate and extent of absorption of a drug from different drug products containing the same active ingredient. In other words, it compares the bioavailability of a generic drug product to that of a reference drug product. Bioequivalence studies are conducted to ensure that a generic drug product is therapeutically equivalent to the reference drug product and can be used interchangeably.\n",
      "\n",
      "Bioavailability studies are conducted during the development of a drug product to determine its pharmacokinetic profile, while bioequivalence studies are conducted to demonstrate that a generic drug product is equivalent to the reference drug product in terms of its pharmacokinetic properties.\n",
      "\n",
      "[Page: 1, 2]\n",
      "Human: 您能解释一下生物利用度和生物等效性之间的区别吗？?\n",
      "Assistant: 生物利用度是指活性药物成分从药物产品中被吸收并在作用部位可用的速度和程度。它是衡量药物达到体内循环并达到作用部位的数量和速率的指标。生物利用度研究用于确定药物的药代动力学特性，包括其吸收、分布、代谢和排泄。\n",
      "\n",
      "另一方面，生物等效性是指含有相同活性成分的不同药物产品的吸收速度和程度的相似性。换句话说，它比较了仿制药与参比药物产品的生物利用度。生物等效性研究旨在确保仿制药与参比药物产品在药代动力学特性上是治疗等效的，并可以互换使用。\n",
      "\n",
      "生物利用度研究在药物产品开发过程中进行，以确定其药代动力学特性，而生物等效性研究则是为了证明仿制药与参比药物产品在药代动力学特性上是等效的。\n",
      "\n",
      "[页码：1, 2]\n",
      "Human: What are some of the methods recommended for documenting bioavailability and bioequivalence in these studies?\n",
      "Assistant: The recommended methods for documenting bioavailability (BA) and bioequivalence (BE) in these studies include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo BA, pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. PK studies are the most commonly used method and involve measuring the rate and extent of absorption of the active ingredient or moiety in an accessible biological matrix such as blood, plasma, or serum. These studies rely on PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax) to assess the extent and rate of systemic exposure.\n",
      "\n",
      "In vitro tests predictive of human in vivo BA, also known as in vitro-in vivo correlation, can be used to measure the release of the drug substance from the drug product into the systemic circulation. PD studies assess the relationship between the concentration of the active moiety and its therapeutic effect. Studies with clinical benefit endpoints evaluate the clinical efficacy and safety of the drug product. Other in vitro studies may also be conducted to support the demonstration of BA and BE.\n",
      "\n",
      "These methods are described in the FDA's regulations and guidelines for BA and BE studies.\n",
      "\n",
      "[Page: 1, 2, 6]\n",
      "Human: 在这些研究中推荐使用哪些方法来记录生物利用度和生物等效性？\n",
      "Assistant: 回答：在这些研究中，推荐使用的方法包括药代动力学（PK）研究、预测人体内生物利用度的体外试验、药效动力学（PD）研究、以临床效益为终点的研究和其他体外研究。PK研究是最常用的方法，涉及测量活性成分或成分在血液、血浆或血清等可获取的生物基质中的吸收速率和程度。这些研究依赖于PK指标，如曲线下面积（AUC）、最大浓度（Cmax）和达到最大浓度的时间（Tmax），以评估系统暴露的程度和速率。\n",
      "\n",
      "预测人体内生物利用度的体外试验，也称为体外-体内相关性，可用于测量药物成分从药物产品释放到体内循环的程度。药效动力学研究评估活性成分浓度与其治疗效果之间的关系。以临床效益为终点的研究评估药物产品的临床疗效和安全性。还可以进行其他体外研究来支持生物利用度和生物等效性的证明。\n",
      "\n",
      "这些方法在FDA的法规和指南中有详细描述。\n",
      "\n",
      "[页码：1, 2, 6]\n",
      "Follow Up Input: 药效动力学？\n",
      "Standalone question:\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new StuffDocumentsChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3m\n",
      "    指令：\n",
      "    1. 你必须只根据以下文本的内容及谈话记录回答提问者的询问。\n",
      "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
      "    3. 请以少於200字回答问题。\n",
      "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
      "    5. 通过谈话记录允许聊天继续\n",
      "    \n",
      "    文本： \n",
      " \n",
      " \n",
      "   \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Draft — Not for Implementation \n",
      "Contains Nonbinding Recommendations \n",
      "853 use the highest strength of the combination product with matching doses of individual \n",
      "854 drug products. \n",
      "855 \n",
      "856  Certain alternative study designs may also be acceptable depending on the specific \n",
      "857 situation. For instance, in the case of  a combination product consisting of two \n",
      "858 components, a three-treatment study desi gn comparing the combination drug product \n",
      "859 versus single-ingredient drug products admi nistered separately may be appropriate. \n",
      "860 861  A single-dose, food-effect study on the combination drug product. \n",
      "862 \n",
      "863 BE studies for the combination product s hould include the measurement of systemic \n",
      "864 concentrations of each active ingredient.  The co nfidence interval approach should be applied to \n",
      "865 each measured entity of the combination drug product and its reference product.  \n",
      "866 867 In specific cases, drug products are given in comb ination (not co-formulated) with the objective \n",
      "868 of increasing the exposure of one of the drugs (s ubject drug).  The second drug is not intended to \n",
      "869 have a therapeutic effect and is given only to in crease the systemic exposure of the subject drug.  \n",
      "870 When both the subject and second drug are new mo lecular entities, the BA of each should be \n",
      "871 assessed separately. If a BE study is needed for the subject drug for any reason, the subject drug \n",
      "872 should be administered with the second drug for both test and reference products.  The \n",
      "873 corresponding PK results, includi ng confidence intervals for BE crite ria, should be applied to the \n",
      "874 subject drug. It is not necessa ry to measure the concentrations  of the second drug.  BE studies \n",
      "875 that are needed for the second drug should be conducted only with the second drug; the subject \n",
      "876 drug is not dosed with the second drug.  When the combination includes a new molecular entity \n",
      "877 and an approved product, only the BA of the new molecular entity should be assessed.  It is \n",
      "878 assumed that the BA of the approved product has been previously evaluated.    \n",
      "879 \n",
      "880 G. Endogenous Substances \n",
      "881 \n",
      "882 Drug products can be developed that contain compounds that are endog enous to humans (e.g., \n",
      "883 testosterone). When the endogenous compounds are identical to the drug that is being \n",
      "884 administered, determining the amount of drug re leased from the dosage form and absorbed by \n",
      "885 each subject is difficult. In most cases, it is important to measure and approximate the baseline \n",
      "886 endogenous levels of the compound in blood (plasma)  and subtract these levels from the total \n",
      "887 concentrations measured from each subject after the drug product is administered.  In this way, \n",
      "888 an estimate of actual drug availability from the drug product can be achieved, and therefore BA \n",
      "889 and BE can be assessed. Endogenous substances may have homeostatic processes that affect \n",
      "890 their production and therefore imp act their systemic concentrati ons. To reduce the complication \n",
      "891 of these homeostatic processes and to potentia lly avoid the need for baseline correction, an \n",
      "892 alternative approach might be to  enroll patients in BA and BE studies with low or no production \n",
      "893 of the endogenous substances in stead of healthy volunteers. \n",
      "894 895 Baseline concentrations of th e endogenous substance produced by the body are measured in the \n",
      "896 time period prior to study drug administra tion.  Depending on the proposed indication, \n",
      "897 subtraction of the time-averaged baseline or time-matched baseline from the post-dose \n",
      "22\n",
      " \n",
      "\n",
      " \n",
      " Draft — Not for Implementation \n",
      " \n",
      "Contains Nonbinding Recommendations \n",
      " \n",
      "487  \n",
      "488 1.  Preapproval Changes \n",
      "489  \n",
      "490 For BA and BE studies, we recommend a singl e-dose, fasting study be performed.  Under \n",
      "491 certain circumstances, multiple-dose BA studies  (see section III.A.5) and/or food effect \n",
      "492 studies may be necessary (See the FDA guidance for industry Food-Effect Bioavailability \n",
      "493 and Fed Bioequivalence). Unconventional dosage forms (buccal, chewable, orally \n",
      "494 disintegrating, and sublingua l dosage forms) should be administered according to \n",
      "495 intended label use/instructi ons.  In addition, a BA study may be needed with the \n",
      "496 unconventional dosage form swallowed intact  to assess the impact of accidental \n",
      "497 swallowing of the intact product. Sampling should adequately capture the T max and C max  \n",
      "498 in addition to total exposure. \n",
      "499  \n",
      "500 We recommend that in vitro dissolution be eval uated for all orally administered products.  \n",
      "501 In vitro dissolution test conditions could be the same or different for unconventional \n",
      "502 compared to conventional dosage forms.  If di fferences in dissolution data exist, they \n",
      "503 should be discussed with the appropriate review division.  \n",
      "504  \n",
      "505 2.  Postapproval Changes \n",
      "506  \n",
      "507 Information on the types of in vitro disso lution and in vivo BE studies needed for \n",
      "508 approved immediate-release drug products when postapproval changes are made is \n",
      "509 provided in an FDA guidance for industry entitled SUPAC-IR: Immediate Release Solid \n",
      "510 Oral Dosage Forms Scale-Up and Postapprov al Changes: Chemistry, Manufacturing, \n",
      "511 and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation . \n",
      "512 We recommend that for postapproval changes, th e in vitro or in vivo comparison be made \n",
      "513 between the post-change and pre-change products. \n",
      "514  \n",
      "515 C.  Modified-Release Products  \n",
      "516  \n",
      "517 Modified-release (MR) products include exte nded-release (controlled-release, sustained-\n",
      "518 release)17 and delayed-release products. \n",
      "519  \n",
      "520 Extended-release (ER) products are dosage forms that are designed to extend or prolong the \n",
      "521 release of active ingredient or  active moiety from the drug pr oduct and may allow a reduction in \n",
      "522 dosing frequency as compared to when the drug is administered in an immediate-release (IR) \n",
      "523 dosage form. These drug products can be developed to reduce fluctuations in plasma  \n",
      "524 concentrations when compared to an IR product. ER products can be capsules, tablets, granules, \n",
      "525 pellets, or suspensions. \n",
      "526  \n",
      "527 Delayed-release (DR) drug products are dosage fo rms that release active ingredient or active \n",
      "528 moiety at a time later than immediately after administration (i.e., these drug products exhibit a \n",
      "529 lag time in quantifiable plasma concentrations).  Typically, coatings (e.g. , enteric coatings) are \n",
      "                                                 \n",
      "17  For the purpose of this guidance, the terms extended , controlled , and  sustained are used interchangeably. \n",
      "13\n",
      "\n",
      " \n",
      "\n",
      "272 21 CFR Ch. I (4–1–22 Edition) § 14.100 \n",
      "(ii) Function: Reviews and evaluates \n",
      "data on the safety and effectiveness of marketed and investigational human drugs for use in the treatment of pul-monary disease and diseases with aller-gic and/or immunologic mechanisms. \n",
      "(14) Medical Imaging Drugs Advisory \n",
      "Committee. \n",
      "(i) Date established: May 18, 2011. (ii) Function: Reviews and evaluates \n",
      "data concerning the safety and effec-tiveness of marketed and investiga-tional human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radi-ology. \n",
      "(15) Pharmaceutical Science and Clin-\n",
      "ical Pharmacology Advisory Committee. \n",
      "(i) Date established: January 22, 1990. (ii) Function: The committee shall \n",
      "provide advice on scientific, clinical and technical issues related to safety and effectiveness of drug products for use in the treatment of a broad spec-trum of human diseases, the quality characteristics which such drugs pur-port or are represented to have and as required, any other product for which the Food and Drug Administration has regulatory responsibility, and make appropriate recommendations to the Commissioner of Food and Drugs. The Committee may also review agency sponsored intramural and extramural biomedical research programs in sup-port of FDA’s drug regulatory respon-sibilities and its critical path initia-tives related to improving the efficacy and safety of drugs and improving the efficiency of drug development. \n",
      "(16) Nonprescription Drugs Advisory \n",
      "Committee. \n",
      "(i) Date established: August 27, 1991. (ii) Functions: The committee re-\n",
      "views and evaluates available data con-cerning the safety and effectiveness of over-the-counter (nonprescription) human drug products for use in the treatment of a broad spectrum of human symptoms and diseases. \n",
      "(17) Pharmacy Compounding Advisory \n",
      "Committee. \n",
      "(i) Date re-established: April 25, 2012. (ii) Function: Provides advice on sci-\n",
      "entific, technical, and medical issues concerning drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and, as required, any other product for which \n",
      "the Food and Drug Administration has regulatory responsibility, and makes appropriate recommendations to the Commissioner of Food and Drugs. \n",
      "(d) Center for Devices and Radiological \n",
      "Health — \n",
      "(1) Medical Devices Advisory Committee. \n",
      "(i) Date established: October 27, 1990. \n",
      "(ii) Function: Reviews and evaluates \n",
      "data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation. \n",
      "(2) Device Good Manufacturing Practice \n",
      "Advisory Committee. \n",
      "(i) Date established: May 17, 1987. (ii) Function: Reviews proposed regu-\n",
      "lations for good manufacturing prac-tices governing the methods used in, and the facilities and controls used for, the manufacture, packing, storage, and installation of devices, and makes rec-ommendations on the feasibility and reasonableness of the proposed regula-tions. \n",
      "(3) Technical Electronic Product Radi-\n",
      "ation Safety Standards Committee. \n",
      "(i) Date established: October 18, 1968. (ii) Function: Advises on technical \n",
      "feasibility, reasonableness, and prac-ticability of performance standards for electronic products to control the emission of radiation under 42 U.S.C. 263f(f)(1)(A). \n",
      "(4) National Mammography Quality As-\n",
      "surance Advisory Committee. \n",
      "(i) Date established: July 6, 1993. (ii) Function: Advises on developing \n",
      "appropriate quality standards and reg-ulations for the use of mammography facilities. \n",
      "(5) Patient Engagement Advisory Com-\n",
      "mittee. \n",
      "(i) Date Established: October 6, 2015. (ii) Function: Provides advice to the \n",
      "Commissioner on complex issues relat-ing to medical devices, the regulation of devices, and their use by patients. Agency guidance and policies, clinical trial or registry design, patient pref-erence study design, benefit-risk deter-minations, device labeling, unmet clin-ical needs, available alternatives, pa-tient reported outcomes, and device-re-lated quality of life or health status issues are among the topics that may be considered by the Committee. The Committee provides relevant skills and \n",
      "VerDate Sep<11>2014 10:27 Aug 01, 2022 Jkt 256071 PO 00000 Frm 00282 Fmt 8010 Sfmt 8010 Q:\\21\\21V1.TXT PC31kpayne on VMOFRWIN702 with $$_JOB\n",
      "\n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      "  \n",
      "  \n",
      " \n",
      "   Draft — Not for Implementation \n",
      "Contains Nonbinding Recommendations \n",
      "640 For example, in some instances, in vivo BA or BE  is self-evident based on certain characteristics \n",
      "641 of the drug product (21 CFR 320.22(b )), and therefore, any in vi vo data requirement has been \n",
      "642 deemed to have been met.  In other delineated circumstances, an in vivo BA or BE data \n",
      "643 requirement may be waived, and in vitro data may be accepted in lieu of in vivo data (21 CFR \n",
      "644 320.22(d)). For example, an in vivo data requirem ent may be waived for different strengths of \n",
      "645 an immediate-release drug product under 21 CF R 320.22(d)(2) when (1) the drug product is in \n",
      "646 the same dosage form, but in a different strength;  (2) this different strength is proportionally \n",
      "647 similar in its active and inactive ingredient s to another drug product for which the same \n",
      "648 manufacturer has obtained approval;  and (3) the new strength meets an appropriate in vitro test \n",
      "649 as outlined in the regulation.26 In addition, for waiving higher strengths, linearity of the \n",
      "650 pharmacokinetics over the therapeutic dose range should be demonstrated. \n",
      "651 \n",
      "652 This guidance defines proportionally similar in the following ways: \n",
      "653 \n",
      "654  All active and inactive ingredients are in exactly the same proportion between different \n",
      "655 strengths (e.g., a tablet of 50-mg strength has al l the inactive ingredient s, exactly half that \n",
      "656 of a tablet of 100-mg strength, and twice that of a tablet of 25-mg strength). \n",
      "657 658  For high-potency drug substances (where the amount of active dr ug substance in the \n",
      "659 dosage form is relatively low), (1) the total weight of the dosage form remains nearly the \n",
      "660 same for all strengths (within ± 10 % of the to tal weight of the strength on which a BE \n",
      "661 was performed), (2) the same inactive ingredie nts are used for all st rengths, and (3) the \n",
      "662 change in any strength is obtained by altering the amount of the active ingredients and \n",
      "663 one or more of the inactive ingredients.   \n",
      "664 665  Bilayer tablets are considered to be one formulation even though they consist of two \n",
      "666 separate layers with different compositions.  In assessing the proportional similarity of \n",
      "667 the different strengths, all components of both layers should be proportionally similar.  \n",
      "668 The fact that only one layer is proportionally si milar and the other is not clearly indicates \n",
      "669 that the products (whole tablet) are not propor tionally similar. This is relevant because \n",
      "670 there can be interactions between the different tablet layers, which can differ across \n",
      "671 different strengths because of the different size of the layers and the varying amounts of \n",
      "672 excipients present in each layer. \n",
      "673 \n",
      "674 Exceptions to the above definitions may be possibl e if adequate justification is provided and \n",
      "675 discussed with the appropriate review division. \n",
      "676 \n",
      "677 B. In Vitro Studies Conducted in Support of Demonstrating BA or BE \n",
      "678 \n",
      "26 See also 21 CFR 322.22(d)(3) and (4) for additional bases for waiver.  Also, FDA, for good cause, may waive a \n",
      "requirement for the submission of evidence of in vivo bioa vailability or bioequivalence if waiver is compatible with \n",
      "the protection of the public health.  For full NDAs, FDA may defer a requirement for the submission of evidence of \n",
      "in vivo bioavailability if deferral is compatible with the protection of the public health (21 CFR 320.22(e)). \n",
      "17\n",
      " \n",
      "\n",
      "    谈话记录：\n",
      "Human: Can you explain the difference between bioavailability and bioequivalence?\n",
      "Assistant: Bioavailability refers to the rate and extent to which an active drug ingredient is absorbed from a drug product and becomes available at the site of action. It is a measure of the amount of drug that reaches the systemic circulation and the rate at which it reaches it. Bioavailability studies are conducted to determine the pharmacokinetic profile of a drug, including its absorption, distribution, metabolism, and excretion.\n",
      "\n",
      "On the other hand, bioequivalence refers to the similarity in the rate and extent of absorption of a drug from different drug products containing the same active ingredient. In other words, it compares the bioavailability of a generic drug product to that of a reference drug product. Bioequivalence studies are conducted to ensure that a generic drug product is therapeutically equivalent to the reference drug product and can be used interchangeably.\n",
      "\n",
      "Bioavailability studies are conducted during the development of a drug product to determine its pharmacokinetic profile, while bioequivalence studies are conducted to demonstrate that a generic drug product is equivalent to the reference drug product in terms of its pharmacokinetic properties.\n",
      "\n",
      "[Page: 1, 2]\n",
      "Human: 您能解释一下生物利用度和生物等效性之间的区别吗？?\n",
      "Assistant: 生物利用度是指活性药物成分从药物产品中被吸收并在作用部位可用的速度和程度。它是衡量药物达到体内循环并达到作用部位的数量和速率的指标。生物利用度研究用于确定药物的药代动力学特性，包括其吸收、分布、代谢和排泄。\n",
      "\n",
      "另一方面，生物等效性是指含有相同活性成分的不同药物产品的吸收速度和程度的相似性。换句话说，它比较了仿制药与参比药物产品的生物利用度。生物等效性研究旨在确保仿制药与参比药物产品在药代动力学特性上是治疗等效的，并可以互换使用。\n",
      "\n",
      "生物利用度研究在药物产品开发过程中进行，以确定其药代动力学特性，而生物等效性研究则是为了证明仿制药与参比药物产品在药代动力学特性上是等效的。\n",
      "\n",
      "[页码：1, 2]\n",
      "Human: What are some of the methods recommended for documenting bioavailability and bioequivalence in these studies?\n",
      "Assistant: The recommended methods for documenting bioavailability (BA) and bioequivalence (BE) in these studies include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo BA, pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. PK studies are the most commonly used method and involve measuring the rate and extent of absorption of the active ingredient or moiety in an accessible biological matrix such as blood, plasma, or serum. These studies rely on PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax) to assess the extent and rate of systemic exposure.\n",
      "\n",
      "In vitro tests predictive of human in vivo BA, also known as in vitro-in vivo correlation, can be used to measure the release of the drug substance from the drug product into the systemic circulation. PD studies assess the relationship between the concentration of the active moiety and its therapeutic effect. Studies with clinical benefit endpoints evaluate the clinical efficacy and safety of the drug product. Other in vitro studies may also be conducted to support the demonstration of BA and BE.\n",
      "\n",
      "These methods are described in the FDA's regulations and guidelines for BA and BE studies.\n",
      "\n",
      "[Page: 1, 2, 6]\n",
      "Human: 在这些研究中推荐使用哪些方法来记录生物利用度和生物等效性？\n",
      "Assistant: 回答：在这些研究中，推荐使用的方法包括药代动力学（PK）研究、预测人体内生物利用度的体外试验、药效动力学（PD）研究、以临床效益为终点的研究和其他体外研究。PK研究是最常用的方法，涉及测量活性成分或成分在血液、血浆或血清等可获取的生物基质中的吸收速率和程度。这些研究依赖于PK指标，如曲线下面积（AUC）、最大浓度（Cmax）和达到最大浓度的时间（Tmax），以评估系统暴露的程度和速率。\n",
      "\n",
      "预测人体内生物利用度的体外试验，也称为体外-体内相关性，可用于测量药物成分从药物产品释放到体内循环的程度。药效动力学研究评估活性成分浓度与其治疗效果之间的关系。以临床效益为终点的研究评估药物产品的临床疗效和安全性。还可以进行其他体外研究来支持生物利用度和生物等效性的证明。\n",
      "\n",
      "这些方法在FDA的法规和指南中有详细描述。\n",
      "\n",
      "[页码：1, 2, 6]\n",
      "\n",
      "    #####\n",
      "\n",
      "    问题：药效动力学是什么？\n",
      "\n",
      "    \u001b[0m\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'raw': {'question': '药效动力学？',\n",
       "  'chat_history': [HumanMessage(content='Can you explain the difference between bioavailability and bioequivalence?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='Bioavailability refers to the rate and extent to which an active drug ingredient is absorbed from a drug product and becomes available at the site of action. It is a measure of the amount of drug that reaches the systemic circulation and the rate at which it reaches it. Bioavailability studies are conducted to determine the pharmacokinetic profile of a drug, including its absorption, distribution, metabolism, and excretion.\\n\\nOn the other hand, bioequivalence refers to the similarity in the rate and extent of absorption of a drug from different drug products containing the same active ingredient. In other words, it compares the bioavailability of a generic drug product to that of a reference drug product. Bioequivalence studies are conducted to ensure that a generic drug product is therapeutically equivalent to the reference drug product and can be used interchangeably.\\n\\nBioavailability studies are conducted during the development of a drug product to determine its pharmacokinetic profile, while bioequivalence studies are conducted to demonstrate that a generic drug product is equivalent to the reference drug product in terms of its pharmacokinetic properties.\\n\\n[Page: 1, 2]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='您能解释一下生物利用度和生物等效性之间的区别吗？?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='生物利用度是指活性药物成分从药物产品中被吸收并在作用部位可用的速度和程度。它是衡量药物达到体内循环并达到作用部位的数量和速率的指标。生物利用度研究用于确定药物的药代动力学特性，包括其吸收、分布、代谢和排泄。\\n\\n另一方面，生物等效性是指含有相同活性成分的不同药物产品的吸收速度和程度的相似性。换句话说，它比较了仿制药与参比药物产品的生物利用度。生物等效性研究旨在确保仿制药与参比药物产品在药代动力学特性上是治疗等效的，并可以互换使用。\\n\\n生物利用度研究在药物产品开发过程中进行，以确定其药代动力学特性，而生物等效性研究则是为了证明仿制药与参比药物产品在药代动力学特性上是等效的。\\n\\n[页码：1, 2]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='What are some of the methods recommended for documenting bioavailability and bioequivalence in these studies?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content=\"The recommended methods for documenting bioavailability (BA) and bioequivalence (BE) in these studies include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo BA, pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. PK studies are the most commonly used method and involve measuring the rate and extent of absorption of the active ingredient or moiety in an accessible biological matrix such as blood, plasma, or serum. These studies rely on PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax) to assess the extent and rate of systemic exposure.\\n\\nIn vitro tests predictive of human in vivo BA, also known as in vitro-in vivo correlation, can be used to measure the release of the drug substance from the drug product into the systemic circulation. PD studies assess the relationship between the concentration of the active moiety and its therapeutic effect. Studies with clinical benefit endpoints evaluate the clinical efficacy and safety of the drug product. Other in vitro studies may also be conducted to support the demonstration of BA and BE.\\n\\nThese methods are described in the FDA's regulations and guidelines for BA and BE studies.\\n\\n[Page: 1, 2, 6]\", additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='在这些研究中推荐使用哪些方法来记录生物利用度和生物等效性？', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='回答：在这些研究中，推荐使用的方法包括药代动力学（PK）研究、预测人体内生物利用度的体外试验、药效动力学（PD）研究、以临床效益为终点的研究和其他体外研究。PK研究是最常用的方法，涉及测量活性成分或成分在血液、血浆或血清等可获取的生物基质中的吸收速率和程度。这些研究依赖于PK指标，如曲线下面积（AUC）、最大浓度（Cmax）和达到最大浓度的时间（Tmax），以评估系统暴露的程度和速率。\\n\\n预测人体内生物利用度的体外试验，也称为体外-体内相关性，可用于测量药物成分从药物产品释放到体内循环的程度。药效动力学研究评估活性成分浓度与其治疗效果之间的关系。以临床效益为终点的研究评估药物产品的临床疗效和安全性。还可以进行其他体外研究来支持生物利用度和生物等效性的证明。\\n\\n这些方法在FDA的法规和指南中有详细描述。\\n\\n[页码：1, 2, 6]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='药效动力学？', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='药效动力学是研究药物在体内的作用机制和效应的科学领域。它关注药物与生物体之间的相互作用，包括药物的吸收、分布、代谢和排泄，以及药物在体内的药效效应和副作用。药效动力学研究可以评估药物的疗效、安全性和药物治疗的最佳用量和用法。通过药效动力学研究，可以了解药物在体内的药物浓度与其治疗效果之间的关系，从而指导药物的合理使用和剂量调整。\\n\\n[页码：6]', additional_kwargs={}, example=False)],\n",
       "  'answer': '药效动力学是研究药物在体内的作用机制和效应的科学领域。它关注药物与生物体之间的相互作用，包括药物的吸收、分布、代谢和排泄，以及药物在体内的药效效应和副作用。药效动力学研究可以评估药物的疗效、安全性和药物治疗的最佳用量和用法。通过药效动力学研究，可以了解药物在体内的药物浓度与其治疗效果之间的关系，从而指导药物的合理使用和剂量调整。\\n\\n[页码：6]'},\n",
       " 'answer': '药效动力学是研究药物在体内的作用机制和效应的科学领域。它关注药物与生物体之间的相互作用，包括药物的吸收、分布、代谢和排泄，以及药物在体内的药效效应和副作用。药效动力学研究可以评估药物的疗效、安全性和药物治疗的最佳用量和用法。通过药效动力学研究，可以了解药物在体内的药物浓度与其治疗效果之间的关系，从而指导药物的合理使用和剂量调整。\\n\\n[页码：6]',\n",
       " 'source': 'Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-—-General-Considerations.pdf',\n",
       " 'website_url': '/',\n",
       " 'page_no': '/',\n",
       " 'first_page_no': '',\n",
       " 'language': '-'}"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = \"药效动力学？\"\n",
    "llm_pipeline_with_history(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'history' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[12], line 11\u001b[0m\n\u001b[0;32m      7\u001b[0m             \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAI: \u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;241m+\u001b[39m message\u001b[38;5;241m.\u001b[39mcontent)\n\u001b[0;32m      8\u001b[0m         i\u001b[38;5;241m+\u001b[39m\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m\n\u001b[1;32m---> 11\u001b[0m retrieve_chat_history(history)\n",
      "\u001b[1;31mNameError\u001b[0m: name 'history' is not defined"
     ]
    }
   ],
   "source": [
    "def retrieve_chat_history(history):\n",
    "    i = 0\n",
    "    for message in history.messages:\n",
    "        if i % 2 == 0:\n",
    "            print(\"Human: \" + message.content)\n",
    "        else:\n",
    "            print(\"AI: \" + message.content)\n",
    "        i+=1\n",
    "\n",
    "\n",
    "retrieve_chat_history(history)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip show langchain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip show azure-search-documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# do not run, not use this for memory\n",
    "\n",
    "def llm_pipeline(question):\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "\n",
    "    # retrieve information from Azure Search\n",
    "    relevant_docs, source, website_url, language, page_no = azure_search_by_index(question, index_name)\n",
    "\n",
    "    #print(relevant_docs)\n",
    "\n",
    "    # generate prompt without example\n",
    "\n",
    "    if language == \"en\":\n",
    "    #english prompt\n",
    "        PROMPT = generate_prompt()\n",
    "    else:\n",
    "        PROMPT = generate_prompt_chi()\n",
    "\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "\n",
    "    # use AzureChatOpenAI \n",
    "    llm = AzureChatOpenAI(deployment_name=\"gpt-35-16k\", temperature=0,\n",
    "                        openai_api_version=\"2023-05-15\", openai_api_base=\"https://pwcjay.openai.azure.com/\")\n",
    "\n",
    "\n",
    "    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://gpt-demo-chat-history.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"AZEhMpW4YD3t7iEMgp9at48S7f5ZjvnahUqJMYjMjMpH2QH2wiYBL97RdX7AqL3CMQcGGhbdAFHvACDbDDwMyA==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"sino_demo\"\n",
    "    CONTAINER_NAME = \"sino_chat_history\"\n",
    "    sessionId = \"101\"\n",
    "    user_id = \"Sunny\"\n",
    "\n",
    "    history = CosmosDBChatMessageHistory(\n",
    "        cosmos_endpoint = ENDPOINT,\n",
    "        cosmos_database = DATABASE_NAME,\n",
    "        cosmos_container = CONTAINER_NAME,\n",
    "        credential = KEY,\n",
    "        session_id = sessionId,\n",
    "        user_id = user_id,\n",
    "    )\n",
    "\n",
    "    history.prepare_cosmos()\n",
    "\n",
    "\n",
    "\n",
    "    # add chat memory\n",
    "    memory = ConversationBufferMemory(\n",
    "        llm = llm,\n",
    "        output_key='answer',\n",
    "        memory_key='chat_history',\n",
    "        chat_memory=history,\n",
    "        return_messages=True\n",
    "    )\n",
    "\n",
    "    chain = LLMChain(llm=llm, \n",
    "                    prompt=PROMPT,\n",
    "                    memory=memory\n",
    "                   #verbose=True\n",
    "                    )\n",
    "\n",
    "    output = chain.run({\"context\": relevant_docs, #\"context\": relevant_docs, \n",
    "        \"question\": question,\n",
    "        })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip install azure-cosmos"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
